drugset / Trial / NCT07288814
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Phase 1/2
Not yet recruiting
43 enrolled
Sun Yat-sen University Cancer Center
CSPC Ouyi Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of mitoxantrone hydrochloride liposome combined with enlonstobart in the treatment of relapsed or refractory peripheral T-cell lymphoma, to determine the optimal dosage of mitoxantrone hydrochloride liposome within the combination regimen, and to assess the efficacy of the combined therapy.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enlonstobart | Monoclonal antibody | 360 mg | — |
| Subject | Mitoxantrone | Small molecule | 16 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | — |